Skip to main content
    A

    Armata Pharmaceuticals Inc (ARMP)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • AMEX

    $2.99
    -0.88 (-22.74%)

    Market Cap: $143.94M

    Last updated: Nov 17, 2026 at 11:03 AM ET

    Armata Pharmaceuticals Inc (ARMP) Competitors

    Updated Nov 17, 2026. Similar companies are ranked by business profile, size, sector and industry; metrics come from company filings and market prices.

    The companies most similar to Armata Pharmaceuticals are Invivyd (IVVD), Protara Therapeutics (TARA) and Fate Therapeutics (FATE). By market cap, Armata Pharmaceuticals ranks 10th of the 13 companies on this page; Arcturus Therapeutics Holdings (ARCT) is the largest at $240.96M.

    Peer Comparison

    ARMP's ROIC of -184.6% is below the peer median of -47.9%, and its revenue growth of 173.6% is above the median of 0.0%. Like the median peer, it pays no dividend.

    CompanyMarket capP/EP/SNet marginROICRev growthDiv yield
    Armata Pharmaceuticals (ARMP)$143.94MN/A14.7x0.0%-184.6%173.6%0.00%
    Invivyd Inc. (IVVD)$171.58MN/A2.9x-183.9%N/A21.2%0.00%
    Protara Therapeutics Inc (TARA)$155.77MN/AN/A0.0%N/A0.0%0.00%
    Fate Therapeutics Inc (FATE)$155.74MN/A29.7x0.0%-51.3%9.2%0.00%
    Arcturus Therapeutics Holdings Inc (ARCT)$240.96MN/A7.7x-285.9%N/A6.7%0.00%
    Innate Pharma (IPHA)$154.15MN/A17.6x0.0%489.8%16.5%0.00%
    Compass Therapeutics Inc. (CMPX)$139.35MN/AN/A0.0%N/A0.0%0.00%
    MacroGenics Inc (MGNX)$140.60MN/A1.2x-36.6%-108.7%-64.8%0.00%
    Upstream Bio, Inc. (UPB)$152.38MN/A41.0x0.0%N/A-42.2%0.00%
    Atrium Therapeutics, Inc. Common Stock (RNA)$162.00MN/A3.3x-180.9%-44.5%24.2%0.00%
    Palisade Bio Inc (PALI)$201.01MN/A436.8x0.0%N/A0.0%0.00%
    Pyxis Oncology Inc (PYXS)$188.98MN/A11.6x0.0%N/A0.0%0.00%
    Anixa Biosciences Inc (ANIX)$91.08MN/AN/A0.0%N/A0.0%0.00%
    Peer median$155.76MN/A11.6x0.0%-47.9%0.0%0.00%
    Market data as of Nov 17, 2026. Net margin covers the trailing 12 months, Rev growth compares the latest quarter with a year earlier and Div yield is the forward yield. P/E uses earnings per share for the last 12 months as companies report it, often adjusted, so it can show beside a negative net margin, which uses net income. P/E and P/S show N/A when those earnings or sales are negative or missing, or the multiple is above 1,000x.

    Similar Companies

    These are the 12 companies most similar to Armata Pharmaceuticals, ranked by how closely their business, size, sector and industry match. All 12 are in one industry, Biotechnology.

    CompanyAboutPeers
    Invivyd Inc. (IVVD)
    Adagio Therapeutics, Inc., a clinical-stage biopharmaceutical company, is focused on the discovery...
    IVVD competitors
    Protara Therapeutics Inc (TARA)
    Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, is dedicated to identifying and promoting transformative therapies for the treatment...
    TARA competitors
    Fate Therapeutics Inc (FATE)
    Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders globally.
    FATE competitors
    Arcturus Therapeutics Holdings Inc (ARCT)
    Arcturus Therapeutics Holdings Inc., an RNA drug company, focuses on the treatment of liver and respiratory diseases.
    ARCT competitors
    Innate Pharma (IPHA)
    Innate Pharma SA, a biotechnology company, discovers, develops and markets therapeutic antibodies for the treatment of oncological indications in France...
    Compass Therapeutics Inc. (CMPX)
    Compass Therapeutics, Inc. is a clinical-stage oncology-focused biopharmaceutical company developing proprietary antibody-based therapies to treat multiple...
    CMPX competitors
    MacroGenics Inc (MGNX)
    MacroGenics, Inc., a biopharmaceutical company, discovers and develops antibody-based therapies to treat cancer in the United States.
    MGNX competitors
    Upstream Bio, Inc. (UPB)
    Upstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases that focuses on severe respiratory disorders.
    UPB competitors
    Atrium Therapeutics, Inc. Common Stock (RNA)
    Avidity Biosciences, Inc., a biopharmaceutical company, is dedicated to the development of oligonucleotide-based therapies.
    RNA competitors
    Palisade Bio Inc (PALI)
    Leading BioSciences, Inc. develops therapies to improve human health through therapeutic protection of the gastrointestinal mucosal barrier.
    PALI competitors
    Pyxis Oncology Inc (PYXS)
    Pyxis Oncology, Inc., a preclinical biotechnology company, is dedicated to developing antibody-drug conjugate (ADC) and monoclonal antibody (mAb)...
    PYXS competitors
    Anixa Biosciences Inc (ANIX)
    Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases.
    ANIX competitors

    Frequently Asked Questions About ARMP

    Who are Armata Pharmaceuticals' main competitors?

    The companies most similar to Armata Pharmaceuticals include Invivyd (IVVD), Protara Therapeutics (TARA), Fate Therapeutics (FATE), Arcturus Therapeutics Holdings (ARCT) and Innate Pharma (IPHA), listed from the closest match.

    Who is Armata Pharmaceuticals' biggest competitor?

    Arcturus Therapeutics Holdings (ARCT) is the largest of the similar companies at $240.96M; Invivyd (IVVD) is the closest match by business profile, size, sector and industry.

    How does ARMP stock compare with its competitors?

    ARMP's P/S is 14.7x against a peer median of 11.6x; its net margin is 0.0% against a peer median of 0.0%.

    Which of Armata Pharmaceuticals' competitors pays a higher dividend?

    Armata Pharmaceuticals pays no dividend. None of the similar companies with available yields has a higher forward dividend yield.

    Is Armata Pharmaceuticals bigger than its competitors?

    No. Armata Pharmaceuticals is 10th by market cap among the 13 companies on this page; the largest is Arcturus Therapeutics Holdings (ARCT) at $240.96M.